NEW YORK (GenomeWeb News) — Accelr8 Technology today said that total year-end revenue fell by more than half as net losses increased by roughly half.
 
Revenue for the 12 months ended July 31 slid to $212,000 from $500,000 in 2005, and the company lost $3 million on the year, about 50 percent more than last year.
 
The company said in 2006 it completed its transition to an R&D operation, with its resources directed towards its BACcelr8r platform, particularly towards its BACcel-1.0.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.